Med. praxi. 2015;12(4):192-194 [Neurol. praxi. 2015;16(4):231-235]
Glatiramer acetate and treatment of multiple sclerosis
- 1 Neurologie &ndash, RS centrum s.r.o., Hradec Králové
- 2 Neurologická klinika LF UK a FN Hradec Králové
- 3 Radiologická klinika LF UK a FN Hradec Králové
The 2010 revised McDonald criteria reflect the clinical requirement to establish the diagnosis of multiple sclerosis (MS) as early as the initial attack of neurological symptoms, in an early stage – that of clinically isolated syndrome (CIS). CIS is the indication for a diagnostic triad of paraclinical investigations that can support the hypothesis of the initial demyelinating attack of MS and predict the likelihood of conversion to clinically definite MS – CDMS. Early diagnosis is required to meet the need for early MS treatment. Treatment with glatiramer acetate (GA) or other medicinal products for the first-line treatment of MS (interferon-beta or teriflunomide) is of essential importance in reducing the risk of conversion to CDMS and in the therapeutic strategy for influencing MS prognosis. The case report presents treatment of MS with glatiramer acetate following the initial demyelinating attack of MS.
Keywords: clinically isolated syndrome, multiple sclerosis, McDonald criteria, magnetic resonance imaging, glatiramer acetate
Published: September 19, 2015 Show citation
References
- Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, Lavie M, Gurevich M, Dolev M, Magalashvili D, Barak Y. Intravenous imunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomised, double-blind, placebo-controled trial. Arch Neurol 2004; 61: 1515-1520.
Go to original source... - Banwell BL. Pediatric multiple sclerosis. Curr Neurol Neurosci Rep 2004; 4: 245-252. Go to original source...
Go to PubMed... - Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007; 6: 887-902. Go to original source...
- Claussen MC, Kom T. Immune mechanismus of new therapeutic strategies in MS - Teriflunomide. Clinical Immunology 2012; 142: 49-56. Go to original source...
- Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandéz O, Hartung HP, Seeldrayers P, S?rensen PS, Rovaris M, Martinelli V, Hommes OR. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82. Go to original source...
- Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patiens with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo controlled trial. Lancet 2009; 374: 1503-1511. Go to original source...
- Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet neurol 2005; 4: 567-575. Go to original source... Go to PubMed...
- Gold R, Wolinsky JS. Patophysiology of multiple sclerosis and the place of teriflunomid. Acta Neurol Scand 2011; 124: 75-84. Go to original source... Go to PubMed...
- Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.N Engl J Med 2000; 343: 898-904. Go to original source...
- Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Radű EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C, for the BENEFIT Study Group. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-years active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987-997. Go to original source...
- Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249. Go to original source... Go to PubMed...
- Lehmann HC, Hartung HP, Hetzel GR, Stűve O, Kieseir BC. Plasma exchange in neuroimmunological disorders: Part 1: rationale and treatment of inflamatiory central nervous systém disorders. Arch neurol 2006; 63: 930-935. Go to original source... Go to PubMed...
- McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, Van Den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic kriteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121-127. Go to original source...
- Montalban X, Tintoré M, Swanton J, Barkhof F, Fazekas F, Filippi M, Frederiksen J, Kappos L, Palace J, Polman C, Rovaris M, De Stefano N, Thompson A, Yousry T, Rovira A, Miller DH. MRI kriteria for MS in patiens with clinically isolated syndromes. Neurology 2010; 74: 427-434. Go to original source... Go to PubMed...
- Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G. No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for Treatment of relapsing-Remitting Multiple Sclerosis. Adv Ther; www.advancesintherapy.com; 21 November 2014. Go to original source...
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wolheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. ANN NEUROL 2011; 69: 292-302. Go to original source... Go to PubMed...
- Talab R. Glatiramer acetat. Farmakoterapie. 2006; 3: 271-276.
- Tintoré M, Rovira A, Brieva L, Grivé E, Jardí R, Borrás C, Montalban X. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Multiple sclerosis (Houndmills, Basingstoke, England) 2001; 7: 359-363. Go to original source... Go to PubMed...
- Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MR findings, and outcome of optic neuritis in children. Neurology 2006; 67: 258-262. Go to original source... Go to PubMed...